Price
$15.16
Increased by +0.80%
Dollar Volume
18.99 M
ADR%
7.15
Earnings Report Date (estimate)
Mar 13, 23 (-0.51)
Market Cap.
745.25 M
Shares Float
40.06 M
Shares Outstanding
49.16 M
Beta
0.19
Price / Earnings
-6.35
BPR
434.11
20D Range
12.30 17.17
50D Range
8.29 17.17
200D Range
3.83 23.48
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 10, 22 -0.48
Increased by +40.74%
-0.50
Increased by +4.00%
Aug 11, 22 -0.42
Increased by +30.00%
-0.47
Increased by +10.64%
May 12, 22 -0.44
Decreased by -15.79%
-0.58
Increased by +24.14%
Mar 15, 22 -0.57
Decreased by -235.29%
-0.65
Increased by +12.31%
Nov 9, 21 -0.81
Decreased by -50.00%
-0.39
Decreased by -107.69%
Aug 10, 21 -0.60
Increased by +36.17%
-0.50
Decreased by -20.00%
May 17, 21 -0.38
Decreased by -46.15%
-0.47
Increased by +19.15%
Feb 25, 21 -0.17
Increased by +32.00%
-0.75
Increased by +77.33%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 2.00 K
Decreased by -98.73%
-23.52 M
Increased by +29.83%
Decreased by -1.18 M%
Decreased by -5.43 K%
Jun 30, 22 8.00 K
Decreased by -94.19%
-20.11 M
Increased by +19.01%
Decreased by -251.34 K%
Decreased by -1.29 K%
Mar 31, 22 32.00 K
Decreased by -96.18%
-19.43 M
Decreased by -30.72%
Decreased by -60.72 K%
Decreased by -3.32 K%
Dec 31, 21 -1.13 M
Decreased by -148.79%
73.10 M
Increased by +788.25%
Decreased by -6.48 K%
Decreased by -1.31 K%
Sep 30, 21 157.56 K
Decreased by -94.64%
-33.51 M
Decreased by -88.58%
Decreased by -21.27 K%
Decreased by -3.42 K%
Jun 30, 21 137.62 K
Decreased by -80.93%
-24.83 M
Decreased by -48.07%
Decreased by -18.04 K%
Decreased by -676.41%
Mar 31, 21 837.52 K
Decreased by -62.15%
-14.86 M
Decreased by -282.54%
Decreased by -1.77 K%
Decreased by -910.66%
Dec 31, 20 2.31 M
Increased by +301.65%
-10.62 M
Decreased by -159.28%
Decreased by -459.28%
Increased by +35.45%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.